
The Lancet, a top-ranking medical journal, has published results from pharmaceutical firm Lundbeck’s Deliver study of migraine drug Vyepeti, the firm announced in a press release on Thursday.
“We are incredibly proud that our clinical research is recognized by the medical and scientific community. The publication of the Deliver results by Lancet Neurology is a clear indication that Lundbeck performs clinical research of the highest quality, and that the results of these efforts are relevant to both clinicians and patients,” says Lundbeck Head of R&D Johan Luthman in the statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app